{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T17:02:40Z","timestamp":1778605360590,"version":"3.51.4"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Individualizing induction therapy based on immunological risk is crucial for optimizing outcomes in kidney transplantation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective analysis included 157 first live-donor non-sensitized kidney transplant recipients (KTRs). Within this cohort, 96 individuals exhibited low human leukocyte antigen (HLA) matching (5\u20136 HLA mismatches). The low HLA match subgroup was categorized into 52 KTRs receiving basiliximab alone and 44 recipients treated with a combined single ATG dose of 1.5\u00a0mg\/kg and basiliximab. The primary endpoint was early acute cellular rejection (ACR) within 6\u00a0months post-transplant while secondary outcomes encompassed infection rates, renal allograft function, length of stay (LOS) and readmissions post-transplant.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The incidence of early ACR was decreased for low HLA match KTRs, who received ATG\u2013basiliximab, when compared with low HLA-matched KTRs who received basiliximab alone (9.1% vs 23.9%, P\u00a0=\u00a0.067). Age was a predictor for rejection, and subgroup analysis showed consistent rejection reduction across age groups. No significant differences were observed in admission for transplant LOS or in peri-operative complications, nor in infections rate including BK and cytomegalovirus viremia, allograft function and number of readmissions post-transplant up to 6\u00a0months post-transplant.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In non-sensitized first live-donor KTRs with low HLA matching, a dual ATG\u2013basiliximab induction approach significantly reduced early ACR without compromising safety.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ckj\/sfae236","type":"journal-article","created":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T07:59:14Z","timestamp":1726300754000},"source":"Crossref","is-referenced-by-count":3,"title":["Basiliximab induction alone vs a dual ATG\u2013basiliximab approach in first live-donor non-sensitized kidney transplant recipients with low HLA matching"],"prefix":"10.1093","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9072-7606","authenticated-orcid":false,"given":"Tammy","family":"Hod","sequence":"first","affiliation":[{"name":"Renal Transplant Center, Sheba Medical Center , Tel Hashomer ,","place":["Israel"]},{"name":"Faculty of Medicine, Tel-Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shmuel","family":"Levinger","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Tel-Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enosh","family":"Askenasy","sequence":"additional","affiliation":[{"name":"Renal Transplant Center, Sheba Medical Center , Tel Hashomer ,","place":["Israel"]},{"name":"Faculty of Medicine, Tel-Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6472-7159","authenticated-orcid":false,"given":"Maya","family":"Siman-Tov","sequence":"additional","affiliation":[{"name":"Department of Emergency and Disaster Management, School of Public Health, Faculty of Medicine, Tel-Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yana","family":"Davidov","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Tel-Aviv University , Tel Aviv ,","place":["Israel"]},{"name":"Liver Disease Center, Sheba Medical Center , Tel Hashomer ,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronen","family":"Ghinea","sequence":"additional","affiliation":[{"name":"Renal Transplant Center, Sheba Medical Center , Tel Hashomer ,","place":["Israel"]},{"name":"Faculty of Medicine, Tel-Aviv University , Tel Aviv ,","place":["Israel"]},{"name":"Department of Surgery B, Sheba Medical Center , Tel Hashomer ,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niv","family":"Pencovich","sequence":"additional","affiliation":[{"name":"Renal Transplant Center, Sheba Medical Center , Tel Hashomer ,","place":["Israel"]},{"name":"Faculty of Medicine, Tel-Aviv University , Tel Aviv ,","place":["Israel"]},{"name":"Department of Surgery B, Sheba Medical Center , Tel Hashomer ,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ido","family":"Nachmani","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Tel-Aviv University , Tel Aviv ,","place":["Israel"]},{"name":"Department of Surgery B, Sheba Medical Center , Tel Hashomer ,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eytan","family":"Mor","sequence":"additional","affiliation":[{"name":"Renal Transplant Center, Sheba Medical Center , Tel Hashomer ,","place":["Israel"]},{"name":"Faculty of Medicine, Tel-Aviv University , Tel Aviv ,","place":["Israel"]},{"name":"Department of Surgery B, Sheba Medical Center , Tel Hashomer ,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,9,12]]},"reference":[{"key":"2024112010173951400_bib1","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/tri.12043","article-title":"Selection of induction therapy in kidney transplantation","volume":"26","author":"Hardinger","year":"2013","journal-title":"Transpl Int"},{"key":"2024112010173951400_bib2","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1056\/NEJMoa060068","article-title":"Rabbit antithymocyte globulin versus basiliximab in renal transplantation","volume":"355","author":"Brennan","year":"2006","journal-title":"N Engl J Med"},{"key":"2024112010173951400_bib3","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1097\/TP.0b013e3181a484d7","article-title":"Early outcomes of thymoglobulin and basiliximab induction in kidney transplantation: application of statistical approaches to reduce bias in observational comparisons","volume":"87","author":"Willoughby","year":"2009","journal-title":"Transplantation"},{"key":"2024112010173951400_bib4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/01.tp.0000268084.64888.f3","article-title":"Single bolus antithymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporine triple immunosuppression: efficacy and safety","volume":"84","author":"Kyllonen","year":"2007","journal-title":"Transplantation"},{"key":"2024112010173951400_bib5","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1056\/NEJMc0805714","article-title":"Long-term results of rabbit antithymocyte globulin and basiliximab induction","volume":"359","author":"Brennan","year":"2008","journal-title":"N Engl J Med"},{"key":"2024112010173951400_bib6","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/01.TP.0000129812.68794.CC","article-title":"Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids","volume":"78","author":"Mourad","year":"2004","journal-title":"Transplantation"},{"key":"2024112010173951400_bib7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1046\/j.1600-6135.2003.00274.x","article-title":"Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients","volume":"4","author":"Bustami","year":"2004","journal-title":"Am J Transplant"},{"key":"2024112010173951400_bib8","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1097\/01.TP.0000100826.58738.2B","article-title":"Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation","volume":"76","author":"Cherikh","year":"2003","journal-title":"Transplantation"},{"key":"2024112010173951400_bib9","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1159\/000530855","article-title":"The Clinical manifestation of immunosuppressive therapy as a tool to improve immune monitoring in renal transplant recipients","volume":"48","author":"Scott","year":"2023","journal-title":"Kidney Blood Press Res"},{"key":"2024112010173951400_bib10","doi-asserted-by":"publisher","first-page":"10138","DOI":"10.3389\/ti.2022.10138","article-title":"Alloimmune risk stratification for kidney transplant rejection","volume":"35","author":"Bestard","year":"2022","journal-title":"Transpl Int"},{"key":"2024112010173951400_bib11","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1097\/TP.0000000000002106","article-title":"Association of cold ischemia time with acute renal transplant rejection","volume":"102","author":"Postalcioglu","year":"2018","journal-title":"Transplantation"},{"key":"2024112010173951400_bib12","doi-asserted-by":"publisher","first-page":"149","DOI":"10.6002\/ect.MESOT2021.P73","article-title":"Outcomes of 6 human leukocyte antigen-mismatched living donor kidney transplant: a study with biopsy amendment","volume":"20","author":"Karatas","year":"2022","journal-title":"Exp Clin Transplant"},{"key":"2024112010173951400_bib13","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.humimm.2021.11.005","article-title":"Role of HLA molecular mismatch in clinical practice","volume":"83","author":"Wiebe","year":"2022","journal-title":"Hum Immunol"},{"key":"2024112010173951400_bib14","doi-asserted-by":"publisher","first-page":"12417","DOI":"10.3389\/ti.2024.12417","article-title":"Assessing health-related quality of life in non-directed versus directed kidney donors: implications for the promotion of non-directed donation","volume":"37","author":"Vital","year":"2024","journal-title":"Transpl Int"},{"key":"2024112010173951400_bib15","doi-asserted-by":"publisher","first-page":"10239","DOI":"10.3389\/ti.2022.10239","article-title":"BNT162b2 third booster dose significantly increases the humoral response assessed by both RBD IgG and neutralizing antibodies in renal transplant recipients","volume":"35","author":"Hod","year":"2022","journal-title":"Transpl Int"},{"key":"2024112010173951400_bib16","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/j.1600-6143.2008.02519.x","article-title":"Identifying specific causes of kidney allograft loss","volume":"9","author":"El-Zoghby","year":"2009","journal-title":"Am J Transplant"},{"key":"2024112010173951400_bib17","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1111\/ajt.15299","article-title":"Response to treatment and long-term outcomes in kidney transplant recipients with acute T cell-mediated rejection","volume":"19","author":"Bouatou","year":"2019","journal-title":"Am J Transplant"},{"key":"2024112010173951400_bib18","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1111\/ajt.14627","article-title":"Short-term adverse effects of early subclinical allograft inflammation in kidney transplant recipients with a rapid steroid withdrawal protocol","volume":"18","author":"Mehta","year":"2018","journal-title":"Am J Transplant"},{"key":"2024112010173951400_bib19","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1097\/TP.0000000000002560","article-title":"The impact of early clinical and subclinical T cell-mediated rejection after kidney transplantation","volume":"103","author":"Hoffman","year":"2019","journal-title":"Transplantation"},{"key":"2024112010173951400_bib20","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1111\/ajt.15197","article-title":"The clinical and pathological significance of borderline T cell-mediated rejection","volume":"19","author":"Nankivell","year":"2019","journal-title":"Am J Transplant"},{"key":"2024112010173951400_bib21","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1016\/j.ajt.2023.09.010","article-title":"Characterizing the risk of human leukocyte antigen-incompatible living donor kidney transplantation in older recipients","volume":"23","author":"Long","year":"2023","journal-title":"Am J Transplant"},{"key":"2024112010173951400_bib22","doi-asserted-by":"publisher","first-page":"22387","DOI":"10.1038\/s41598-023-50066-8","article-title":"Prediction of very early subclinical rejection with machine learning in kidney transplantation","volume":"13","author":"Jo","year":"2023","journal-title":"Sci Rep"},{"key":"2024112010173951400_bib23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/ctr.12481","article-title":"Clinical issues in renal transplantation in the elderly","volume":"29","author":"Hod","year":"2015","journal-title":"Clin Transplant"},{"key":"2024112010173951400_bib24","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1111\/j.1600-6143.2007.01860.x","article-title":"Efficacy of anti-IL-2 receptor antibodies compared to no induction and to antilymphocyte antibodies in renal transplantation","volume":"7","author":"Patlolla","year":"2007","journal-title":"Am J Transplant"},{"key":"2024112010173951400_bib25","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1034\/j.1600-6143.2002.020109.x","article-title":"Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy","volume":"2","author":"Lebranchu","year":"2002","journal-title":"Am J Transplant"},{"key":"2024112010173951400_bib26","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.12977","article-title":"The appropriate dose of thymoglobulin induction therapy in kidney transplantation","volume":"31","author":"Nafar","year":"2017","journal-title":"Clin Transplant"},{"key":"2024112010173951400_bib27","doi-asserted-by":"publisher","first-page":"e14582","DOI":"10.1111\/ctr.14582","article-title":"Rabbit antithymocyte globulin dose and early subclinical and clinical rejections in kidney transplantation","volume":"36","author":"Mehta","year":"2022","journal-title":"Clin Transplant"},{"key":"2024112010173951400_bib28","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1080\/08830185.2018.1455194","article-title":"Antithymocytes globulins: time to revisit its use in kidney transplantation?","volume":"37","author":"Ducloux","year":"2018","journal-title":"Int Rev Immunol"},{"key":"2024112010173951400_bib29","doi-asserted-by":"publisher","first-page":"50","DOI":"10.12659\/AOT.881865","article-title":"Single-dose thymoglobulin induction in living-donor renal transplantation","volume":"16","author":"Schenker","year":"2011","journal-title":"Ann Transplant"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfae236\/59107427\/sfae236.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/17\/9\/sfae236\/60764203\/sfae236.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/17\/9\/sfae236\/60764203\/sfae236.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T10:17:52Z","timestamp":1732097872000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfae236\/7756426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfae236","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,9]]},"article-number":"sfae236"}}